CARDIOVASCULAR AND SURVIVAL PARADOXES IN DIALYSIS PATIENTS: Kinetic Studies of Atherogenic Lipoproteins in Hemodialysis Patients: Do They Tell Us More about Their Pathology?

Patients with chronic kidney disease have one of the highest risks for atherosclerotic complications. Several large epidemiological studies described an opposite association of total and low density lipoprotein (LDL) cholesterol with cardiovascular complications and total mortality compared to the general population, a circumstance often called “reverse epidemiology.” Many factors might contribute to this reversal such as interaction with malnutrition/inflammation, pronounced fluctuations of atherogenic lipoproteins during the course of renal disease, heterogeneity of lipoprotein particles with preponderance of remnant particles, and chemical modification of lipoproteins caused by the uremic environment. A vicious cycle has been suggested in uremia in which the decreased catabolism of atherogenic lipoproteins such as LDL, IDL and Lp(a) leads to their increased plasma residence time and further modification of these lipoproteins by oxidation, carbamylation, and glycation. Using stable isotope techniques, it has been shown recently that the plasma residence time of these particles is more than twice as long in hemodialysis patients as in nonuremic subjects. This reduced catabolism, however, is masked by the decreased production of LDL, resulting in near‐normal plasma levels of LDL. The production rate of Lp(a) in hemodialysis patients is similar to that in controls which together with the doubled residence time results in elevated Lp(a) levels. An increased clearance of these altered lipoproteins via the scavenger receptors of macrophages leads to the transformation of macrophages into foam cells in the vascular wall and might contribute to the pronounced risk for cardiovascular complications of these patients. These observations suggest that the real danger of these particles is not reflected by the measured concentrations but by their metabolic qualities.

[1]  F. Kronenberg,et al.  In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients. , 2007, Kidney international.

[2]  F. Kronenberg,et al.  Lipoprotein metabolism and lipid management in chronic kidney disease. , 2007, Journal of the American Society of Nephrology : JASN.

[3]  A. Tall,et al.  The failure of torcetrapib: was it the molecule or the mechanism? , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[4]  F. Kronenberg,et al.  Epidemiology of dialysis patients and heart failure patients. , 2006, Seminars in nephrology.

[5]  F. Kronenberg,et al.  Delayed In Vivo Catabolism of Intermediate-Density Lipoprotein and Low-Density Lipoprotein in Hemodialysis Patients as Potential Cause of Premature Atherosclerosis , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[6]  W. März,et al.  Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. , 2005, The New England journal of medicine.

[7]  K. D. Workgroup K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[8]  F. Kronenberg,et al.  Lipoprotein(a)- and low-density lipoprotein-derived cholesterol in nephrotic syndrome: Impact on lipid-lowering therapy? , 2004, Kidney international.

[9]  J. Romijn,et al.  A broad-based metabolic approach to study VLDL apoB100 metabolism in patients with ESRD and patients treated with peritoneal dialysis. , 2004, Kidney international.

[10]  F. Kronenberg,et al.  The apolipoprotein(a) size polymorphism is associated with nephrotic syndrome. , 2004, Kidney international.

[11]  N. Powe,et al.  Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. , 2004, JAMA.

[12]  F. Kronenberg,et al.  Apolipoprotein(a) isoform-specific changes of lipoprotein(a) after kidney transplantation , 2003, European Journal of Human Genetics.

[13]  J. Jankowski,et al.  The Antioxidant Acetylcysteine Reduces Cardiovascular Events in Patients With End-Stage Renal Failure: A Randomized, Controlled Trial , 2003, Circulation.

[14]  H. Koyama,et al.  Antibody to oxidized low-density lipoprotein and cardiovascular mortality in end-stage renal disease. , 2002, Kidney international.

[15]  N. Powe,et al.  Small Apolipoprotein(a) Size Predicts Mortality in End-Stage Renal Disease: The CHOICE Study , 2002, Circulation.

[16]  Ashutosh Kumar Singh,et al.  Handling of low-density lipoprotein by the renal tubule: release of fragments due to incomplete degradation. , 2002, The Journal of laboratory and clinical medicine.

[17]  F. Kronenberg,et al.  Apolipoprotein A-IV serum concentrations are elevated in patients with mild and moderate renal failure. , 2002, Journal of the American Society of Nephrology : JASN.

[18]  T. Demant,et al.  The metabolism of lipoprotein(a) and other apolipoprotein B-containing lipoproteins: a kinetic study in humans. , 2001, Atherosclerosis.

[19]  P. Lucidi,et al.  Increased albumin and fibrinogen synthesis in hemodialysis patients with normal nutritional status. , 2001, Journal of the American Society of Nephrology : JASN.

[20]  M. Boaz,et al.  Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial , 2000, The Lancet.

[21]  JensPietzsch,et al.  Oxidation of Apolipoprotein B-100 in Circulating LDL Is Related to LDL Residence Time , 2000 .

[22]  Jens Pietzsch,et al.  Oxidation of Apolipoprotein B-100 in Circulating LDL Is Related to LDL Residence Time: In Vivo Insights From Stable-Isotope Studies , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[23]  J. Danesh,et al.  Lipoprotein(a) and Coronary Heart Disease: Meta-Analysis of Prospective Studies , 2000, Circulation.

[24]  F. Kronenberg,et al.  Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. , 2000, Journal of the American Society of Nephrology : JASN.

[25]  Y. Kawaguchi,et al.  Role of hepatic lipase in intermediate-density lipoprotein and small, dense low-density lipoprotein formation in hemodialysis patients. , 1999, Kidney international. Supplement.

[26]  G. Kaysen,et al.  New insights into lipid metabolism in the nephrotic syndrome. , 1999, Kidney international. Supplement.

[27]  F. Kronenberg,et al.  Lipoprotein(a) plasma concentrations after renal transplantation: a prospective evaluation after 4 years of follow-up. , 1999, Atherosclerosis.

[28]  H. Milionis,et al.  Apolipoprotein(a) phenotypes and lipoprotein(a) concentrations in patients with renal failure. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[29]  F. Kronenberg,et al.  The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up. , 1999, Journal of the American Society of Nephrology : JASN.

[30]  C. Wanner,et al.  Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. , 1999, Kidney international.

[31]  R. Foley,et al.  Clinical epidemiology of cardiovascular disease in chronic renal disease. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[32]  J. Haddow,et al.  Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies. , 1998, Clinical chemistry.

[33]  T. Rabelink,et al.  Evidence for increased synthesis of lipoprotein(a) in the nephrotic syndrome. , 1998, Journal of the American Society of Nephrology : JASN.

[34]  T. Shoji,et al.  Intermediate-density lipoprotein as an independent risk factor for aortic atherosclerosis in hemodialysis patients. , 1998, Journal of the American Society of Nephrology : JASN.

[35]  P. Stenvinkel,et al.  Apo(a)-isoform size, nutritional status and inflammatory markers in chronic renal failure. , 1998, Kidney international.

[36]  C. Wanner,et al.  Receptor-mediated lipoprotein uptake by human glomerular cells: comparison with skin fibroblasts and HepG2 cells. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[37]  G. Kaysen Albumin Turnover in Renal Disease , 1997, Mineral and Electrolyte Metabolism.

[38]  F. Kronenberg,et al.  Renovascular arteriovenous differences in Lp[a] plasma concentrations suggest removal of Lp[a] from the renal circulation. , 1997, Journal of lipid research.

[39]  K. Kostner,et al.  Urinary excretion of apo(a) fragments. Role in apo(a) catabolism. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[40]  D. Rader,et al.  ApoA-II kinetics in humans using endogenous labeling with stable isotopes: slower turnover of apoA-II compared with the exogenous radiotracer method. , 1996, Journal of lipid research.

[41]  H. Hobbs,et al.  Apolipoprotein(a) kringle 4-containing fragments in human urine. Relationship to plasma levels of lipoprotein(a). , 1996, The Journal of clinical investigation.

[42]  F. Kronenberg,et al.  Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. , 1995, Journal of the American Society of Nephrology : JASN.

[43]  K. Huttunen,et al.  Decreased clearance of low-density lipoprotein in uremic patients under dialysis treatment. , 1995, Kidney international.

[44]  F. Kronenberg,et al.  Apolipoprotein(a) phenotype-associated decrease in lipoprotein(a) plasma concentrations after renal transplantation. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[45]  F. Kronenberg,et al.  Apolipoprotein(a) phenotypes predict the risk for carotid atherosclerosis in patients with end-stage renal disease. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[46]  K. Huttunen,et al.  Decreased clearance of low-density lipoprotein in patients with chronic renal failure. , 1994, Kidney international.

[47]  D. Rader,et al.  Delayed catabolism of high density lipoprotein apolipoproteins A-I and A-II in human cholesteryl ester transfer protein deficiency. , 1993, The Journal of clinical investigation.

[48]  D. Rader,et al.  Elevated Plasma Lipoprotein(a) in Patients with the Nephrotic Syndrome , 1993, Annals of Internal Medicine.

[49]  F. Kronenberg,et al.  Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a). , 1993, The Journal of clinical investigation.

[50]  S. Grundy,et al.  Influence of lovastatin therapy on metabolism of low density lipoproteins in mixed hyperlipidaemia , 1991, Journal of internal medicine.

[51]  A. del Río [Lipoprotein (a)]. , 1991, Medicina clinica.

[52]  P. Attman,et al.  Lipid and apolipoprotein profiles of uremic dyslipoproteinemia--relation to renal function and dialysis. , 1991, Nephron.

[53]  B. Gordon,et al.  Plasmin catalyzes binding of lipoprotein (a) to immobilized fibrinogen and fibrin. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[54]  Z. Varghese,et al.  Apolipoprotein B turnover in dialysis patients: its relationship to pathogenesis of hyperlipidemia. , 1989, Clinical nephrology.